<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        1-228-10
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2010
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        PLASBUMIN 20% SOLUTION FOR I.V. INJECTION
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        ALBUMIN HUMAN
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        20
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        %
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Intravenous use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Suspension for injection
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        100
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Vial
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Biological
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store in a refrigerator (2°c – 8°c)
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        213.85
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="GRIFOLS THERAPEUTICS LLC" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            GRIFOLS THERAPEUTICS LLC
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 612]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Abdulrehman Algosaibi G.T.C.
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            GRIFOLS THERAPEUTICS INC
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        NA
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Plasbumin-20 is a solution for intravenous infusion containing proteins extracted from human plasma, which is the liquid part of the blood. Each bottle contains a solution of human albumin protein.<br />This medicinal product belongs to a group of medicines known as plasma substitutes and plasma protein fractions.<br />Plasbumin-20 is used to restore and maintain the circulating blood volume where volume deﬁciency has been demonstrated, and use of a plasma substitute is appropriate. The choice of an albumin solution rather than an artiﬁcial plasma substitute will depend on the clinical situation of the individual patient, based on ofﬁcial recommendations.<br />Therapeutic indications:<br />Emergency Treatment of Hypovolemic Shock&nbsp;<br />Burn Therapy<br />Hypoproteinemia With or Without Edema<br />Adult Respiratory Distress Syndrome (ARDS)<br />Cardiopulmonary Bypass<br />Acute Liver Failure<br />Neonatal Hemolytic Disease&nbsp;<br />Sequestration of Protein Rich Fluids<br />Erythrocyte Resuspension<br />Acute Nephrosis<br />Renal Dialysis</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>a. Do not use Plasbumin-20<br />If you are allergic (hypersensitive) to albumin protein or to any of the other ingredients (listed in section 7).&nbsp;<br />b. Take special care with Plasbumin-20<br />Tell your doctor if you have a history of congestive cardiac failure (weak heart), renal insufﬁciency (poor function of the kidneys) or stabilized chronic anemia (absence of red blood cells). These conditions may rule out the use of Plasbumin-20 in your treatment, or cause the doctor to modify the dosage/infusion rate to avoid complications.<br />When medicines are made from human blood or plasma, certain measures are put in place to prevent infections being passed on to patients. These include careful selection of blood and plasma donors to make sure those at risk of carrying infections are excluded, and the testing of each donation and pools of plasma for signs of virus/infections. Manufacturers of these products also include steps in the processing of the blood or plasma that can inactivate or remove viruses. Despite these measures, when medicines prepared from human blood or plasma are administered, the possibility of passing on infection cannot be totally excluded. This applies to any unknown or emerging viruses or other types of infections.<br />No cases of transmission of infections have been identiﬁed for human albumin.<br />c. Taking other medicines, herbal or dietary supplements<br />Please tell your doctor if you are taking or have recently taken any other medicines, including medicines obtained without a prescription. No speciﬁc interactions of human albumin with other medicines are known.<br />d. Using Plasbumin-20 with food and drink<br />There is no information regarding the use of Plabumin-20 with food and drink. Please discuss this with your doctor.<br />e. Pregnancy and breast-feeding<br />Ask your doctor or pharmacist for advice before taking any medicine.</p><p>If you are pregnant or breast-feeding you must tell your doctor who will decide if Plasbumin-20 can be used.&nbsp;</p><p>f.&nbsp;&nbsp; &nbsp;Driving and using machines<br />No effects on the ability to drive and use of machines have been observed.<br />g.&nbsp;&nbsp; &nbsp;Important information about some of the ingredients of Plasbumin-20</p><p>This product contains sodium and may be harmful to people on a low sodium or potassium diet. Tell your doctor if this applies to you.&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Plasbumin-20 is for hospital administration only. It will be administered as an intravenous infusion by medical staff and must not be self-administered. The dosage and the infusion rate you will receive depends upon your medical condition. Your doctor will tell you how often and at what intervals Plasbumin-20 should be given.<br />a. If you use more Plasbumin-20 than you should<br />If you have been given more Plasbumin-20 than required, your blood volume may increase. Signs of overdose may include: headache, trouble breathing, jugular vein congestion (enlarged veins in the neck), high blood pressure, and pulmonary edema (liquid accumulation in the lungs). Tell your doctor immediately if you experience any of these symptoms.<br />b. If you forget to use Plasbumin-20<br />Tell your doctor immediately and follow his/her instructions. You must not be given a double dose to make up for a forgotten dose.<br />c. If you stop using Plasbumin-20<br />If treatment with Plasbumin-20 is stopped, your condition may worsen. Please talk to your doctor if you wish to end treatment with Plasbumin-20 prematurely.<br />If you have any further questions on the use of this product, ask your doctor.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, Plasbumin-20 can cause side effects, although not everybody gets them.<br />Mild side effects such as ﬂushing, hives, fever and nausea occur rarely. These side effects normally disappear rapidly when the infusion rate is slowed down or the infusion is stopped.&nbsp;<br />Very rarely, severe side effects such as shock (lack of blood ﬂow to major organs) may occur. In these cases, the infusion should be stopped and appropriate treatment should be initiated.<br />If any of the side effects get serious, or if you notice any side effects not listed in this leaﬂet, please tell your doctor.&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep out of the reach and sight of children.<br />Do not store above 30&deg;C. Do not freeze. Store in original carton.<br />Do not use Plasbumin-20 after the expiry date which is stated on the bottle label and the carton. Do not use Plasbumin-20 if you notice that the solution is cloudy or has deposits.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The active substance is Albumin (Human), 0.2 g/mL, USP.<br />The other ingredients are sodium caprylate, N-acetyl-DL-tryptophan, sodium (from all sources) and water for injection.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Plasbumin-20 is a clear, slightly viscous, almost colorless to pale yellow, amber or green solution for intravenous infusion.
Plasbumin-20 is available in 50 mL (10 g) and 100 mL (20 g) solution in rubber-stoppered vials. 
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Marketing Authorisation Holder and Manufacturer:<br />Grifols Therapeutics Inc.<br />Research Triangle Park, NC 27709 USA</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This leaflet was last approved in 1/2020; version number 1

            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="LTR">النشره غير مترجمة للعربية حاليا لأن المستحضر يستخدم داخل المستشفى&nbsp;فقط، سوف يتم اضافة النشرة العربية بعد تقديمها واعتمادها من قبل الهيئة</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="LTR">النشره غير مترجمة للعربية حاليا لأن المستحضر يستخدم داخل المستشفى&nbsp;فقط، سوف يتم اضافة النشرة العربية بعد تقديمها واعتمادها من قبل الهيئة</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="LTR">النشره غير مترجمة للعربية حاليا لأن المستحضر يستخدم داخل المستشفى&nbsp;فقط، سوف يتم اضافة النشرة العربية بعد تقديمها واعتمادها من قبل الهيئة</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="LTR">النشره غير مترجمة للعربية حاليا لأن المستحضر يستخدم داخل المستشفى&nbsp;فقط، سوف يتم اضافة النشرة العربية بعد تقديمها واعتمادها من قبل الهيئة</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="LTR">النشره غير مترجمة للعربية حاليا لأن المستحضر يستخدم داخل المستشفى&nbsp;فقط، سوف يتم اضافة النشرة العربية بعد تقديمها واعتمادها من قبل الهيئة</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="LTR">النشره غير مترجمة للعربية حاليا لأن المستحضر يستخدم داخل المستشفى&nbsp;فقط، سوف يتم اضافة النشرة العربية بعد تقديمها واعتمادها من قبل الهيئة</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="LTR">النشره غير مترجمة للعربية حاليا لأن المستحضر يستخدم داخل المستشفى&nbsp;فقط، سوف يتم اضافة النشرة العربية بعد تقديمها واعتمادها من قبل الهيئة</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="LTR">النشره غير مترجمة للعربية حاليا لأن المستحضر يستخدم داخل المستشفى&nbsp;فقط، سوف يتم اضافة النشرة العربية بعد تقديمها واعتمادها من قبل الهيئة</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            النشره غير مترجمة للعربية حاليا لأن المستحضر يستخدم داخل المستشفى فقط، سوف يتم اضافة النشرة العربية بعد تقديمها واعتمادها من قبل الهيئة
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Plasbumin®-20, 0.2 g/mL, Solution for Infusion
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Active Ingredients
Plasbumin®-20, 0.2 g/mL, Solution for Infusion.

Quantitative Composition
Plasbumin-20 is a 20% (0.2 g/mL) sterile solution of albumin in an aqueous diluent. The preparation is stabilized with 0.016 M sodium caprylate and 0.016 M acetyltryptophan. The aluminum content of the product is not more than 200 μg/L. The approximate sodium content of the product is 145 mEq/L. It contains no preservative.
Each vial of Plasbumin-20 is heat-treated at 60°C for 10 hours against the possibility of transmitting the hepatitis viruses.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Solution for intravenous infusion administration.
Plasbumin-20 is clear, slightly viscous, almost colorless to pale yellow, amber or green.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Emergency Treatment of Hypovolemic Shock</p><p>Plasbumin-20 is hyperoncotic and on intravenous infusion will expand the plasma&nbsp;volume by an additional amount, three to four times the volume actually administered by withdrawing fluid from the interstitial spaces, provided the patient is normally hydrated interstitially or there is interstitial edema. If the patient is dehydrated, additional crystalloids must be given, or alternatively, Albumin (Human) 5%, USP (Plasbumin&reg;-5) should be used. The patient&rsquo;s hemodynamic response should be&nbsp;monitored and the usual precautions against circulatory overload observed. The total&nbsp;dose should not exceed the level of albumin found in the normal individual; i.e., about 2 g&nbsp;per kg body weight in the absence of active bleeding. Although Plasbumin-5 is to be preferred for the usual volume deficits, Plasbumin-20 with appropriate crystalloids may offer therapeutic advantages in oncotic deficits or in long-standing shock where<br />treatment has been delayed.</p><p>Removal of ascitic fluid from a patient with cirrhosis may cause changes in&nbsp;cardiovascular function and even result in hypovolemic shock. In such circumstances, the&nbsp;use of albumin infusion may be required to support the blood volume.</p><p>Burn Therapy</p><p>An optimal therapeutic regimen with respect to the administration of colloids,<br />&nbsp;crystalloids, and water following extensive burns has not been established. During the&nbsp;first 24 hours after sustaining thermal injury, large volumes of crystalloids are infused to&nbsp;restore the depleted extracellular fluid volume. Beyond 24 hours Plasbumin-20 can be used to maintain plasma colloid osmotic pressure.</p><p>Hypoproteinemia With or Without Edema</p><p>During major surgery, patients can lose over half of their circulating albumin with the&nbsp;attendant complications of oncotic deficit. A similar situation can occur in sepsis or intensive&nbsp;care patients. Treatment with Plasbumin-20 may be of value in such cases.</p><p>Adult Respiratory Distress Syndrome (ARDS)</p><p>This is characterized by deficient oxygenation caused by pulmonary interstitial edema&nbsp;complicating shock and postsurgical conditions. When clinical signs are those of&nbsp;hypoproteinemia with a fluid volume overload, Plasbumin-20 together with a diuretic may&nbsp;play a role in therapy.</p><p>Cardiopulmonary Bypass</p><p>With the relatively small priming volume required with modern pumps, preoperative dilution of the blood using albumin and crystalloid has been shown to be safe and well-tolerated. Although the limit to which the hematocrit and plasma protein concentration can be safely&nbsp;lowered has not been defined, it is common practice to adjust the albumin and crystalloid<br />pump prime to achieve a hematocrit of 20% and a plasma albumin concentration of 2.5 g&nbsp;per 100 mL in the patient.</p><p>Acute Liver Failure</p><p>In the uncommon situation of rapid loss of liver function with or without coma, administration of albumin may serve the double purpose of supporting the colloid osmotic pressure of the plasma as well as binding excess plasma bilirubin.</p><p>Neonatal Hemolytic Disease</p><p>The administration of Plasbumin-20 may be indicated prior to exchange transfusion, in order&nbsp;to bind free bilirubin, thus lessening the risk of kernicterus. A dosage of 1 g/kg body weight&nbsp;is given about 1 hour prior to exchange transfusion. Caution must be observed in&nbsp;hypervolemic infants.</p><p>Sequestration of Protein Rich Fluids</p><p>This occurs in such conditions as acute peritonitis, pancreatitis, mediastinitis, and extensive cellulitis. The magnitude of loss into the third space may require treatment of reduced volume or oncotic activity with an infusion of albumin.</p><p>Erythrocyte Resuspension</p><p>Albumin may be required to avoid excessive hypoproteinemia during certain types of exchange transfusion, or with the use of very large volumes of previously frozen or washed red cells. About 25 g of albumin per liter of erythrocytes is commonly used, although the&nbsp;requirements in preexistent hypoproteinemia or hepatic impairment can be greater.<br />Plasbumin-20 is added to the isotonic suspension of washed red cells immediately prior to transfusion.</p><p>Acute Nephrosis</p><p>Certain patients may not respond to cyclophosphamide or steroid therapy. The steroids may even aggravate the underlying edema. In this situation a loop diuretic and 100 mL<br />Plasbumin-20 repeated daily for 7 to 10 days may be helpful in controlling the edema and the patient may then respond to steroid treatment.</p><p>Renal Dialysis</p><p>Although not part of the regular regimen of renal dialysis, Plasbumin-20 may be of value in the treatment of shock or hypotension in these patients. The usual volume administered is about 100 mL, taking particular care to avoid fluid overload as these patients are often fluid overloaded and cannot tolerate substantial volumes of salt solution.</p><p>Situations in Which Albumin Administration Is Not Warranted</p><p>In chronic nephrosis, infused albumin is promptly excreted by the kidneys with no relief of the chronic edema or effect on the underlying renal lesion. It is of occasional use in the rapid &ldquo;priming&rdquo; diuresis of nephrosis. Similarly, in hypoproteinemic states associated with chronic cirrhosis, malabsorption, protein losing enteropathies, pancreatic insufficiency, and undernutrition, the infusion of albumin as a source of protein nutrition is not justified.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Posology</p><p>Plasbumin-20 should always be administered by intravenous infusion. Plasbumin-20 may be administered either undiluted or diluted in 0.9% Sodium Chloride or 5% Dextrose in Water.<br />If sodium restriction is required, Plasbumin-20 should only be administered either undiluted or diluted in a sodium-free carbohydrate solution such as 5% Dextrose in Water.</p><p>Hypovolemic Shock</p><p>For treatment of hypovolemic shock, the volume administered and the speed of infusion should be adapted to the response of the individual patient.</p><p>Burns</p><p>After a burn injury (usually beyond 24 hours) there is a close correlation between the amount of albumin infused and the resultant increase in plasma colloid osmotic pressure.<br />The aim should be to maintain the plasma albumin concentration in the region of 2.5 &plusmn; 0.5 g per 100 mL with a plasma oncotic pressure of 20 mm Hg (equivalent to a total plasma protein concentration of 5.2 g per 100 mL). This is best achieved by the intravenous administration of Plasbumin-20. The duration of therapy is decided by the loss of protein from burned areas and in the urine. In addition, oral or parenteral feeding with amino acids should be initiated, as the long-term administration of albumin should not be considered as a source of nutrition.</p><p>Hypoproteinemia With or Without Edema</p><p>Unless the underlying pathology responsible for the hypoproteinemia can be corrected, the&nbsp;intravenous administration of Plasbumin-20 must be considered purely symptomatic or supportive (see section Situations in Which Albumin Administration Is NotWarranted). The usual daily dose of albumin for adults is 50 to 75 g and for children 25 g. Patients with severe hypoproteinemia who continue to lose albumin may require larger quantities. Since hypoproteinemic patients usually have approximately normal blood volumes, the rate of administration of Plasbumin-20 should not exceed 2 mL per minute, as more rapid injection may precipitate circulatory embarrassment and pulmonary edema.<br />Other dosage recommendations are given under the specific indications referred to above.</p><p>Method of Administration</p><p>Plasbumin-20 should always be administered by intravenous infusion.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Certain patients, e.g., those with a history of congestive cardiac failure, renal insufficiency or stabilized chronic anemia, are at special risk of developing circulatory overload.
 A history of an allergic reaction to albumin is a specific contraindication to usage.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Patients should always be monitored carefully in order to guard against the possibility of circulatory overload. Plasbumin-20 is hyperoncotic; therefore, in the presence of dehydration, albumin must be given with or followed by addition of fluids.<br />As with any hyperoncotic protein solution likely to be administered in large volumes, severe hemolysis and acute renal failure may result from the inappropriate use of Sterile Water for Injection as a diluent for Albumin (Human), 20%. Acceptable diluents include&nbsp;0.9% Sodium Chloride or 5% Dextrose in Water. In hemorrhage the administration of albumin should be supplemented by the transfusion of whole blood to treat the relative anemia associated with hemodilution. When circulating blood volume has been reduced, hemodilution following the administration of albumin persists for many hours. In patients with a normal blood volume, hemodilution lasts for a much shorter period.<br />The rapid rise in blood pressure which may follow the administration of a colloid with positive oncotic activity necessitates careful observation to detect and treat severed blood vessels which may not have bled at the lower blood pressure.</p><p>Transmissible Infectious Agents</p><p>Plasbumin-20 is made from human plasma. Products made from human plasma may contain infectious agents, such as viruses, and, theoretically, the Creutzfeldt-Jakob Disease (CJD) agent that can cause disease. The theoretical risk for transmission of CJD is considered extremely remote. No cases of transmission of viral diseases or CJD have ever been identified for albumin. The risk that such products will transmit an infectious agent has been<br />reduced by screening plasma donors for prior exposure to certain viruses, by testing for the&nbsp;presence of certain current virus infections, and by inactivating and/or removing certain viruses. Despite these measures, such products can still potentially transmit disease. There is also the possibility that unknown infectious agents may be present in such products. Individuals who receive infusions of blood or plasma products may develop signs and/or symptoms of some viral infections, particularly hepatitis C. ALL infections thought by a physician possibly to have been transmitted by this product should be reported by the physician or other healthcare provider to Grifols Therapeutics Inc. [1-800-<br />159 520-2807].</p><p>The physician should discuss the risks and benefits of this product with the patient, before prescribing or administering it to the patient.</p><p>Pediatric Use</p><p>Safety and effectiveness in the pediatric population have not been established.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Plasbumin-20 is compatible with whole blood, packed red cells, as well as the standard&nbsp;carbohydrate and electrolyte solutions intended for intravenous use. It should, however, not be mixed with protein hydrolysates, amino acid solutions nor those containing alcohol.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pregnancy Category C</p><p>Animal reproduction studies have not been conducted with Plasbumin-20. It is also not known whether Plasbumin-20 can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Plasbumin-20 should be given to a pregnant woman only if clearly needed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No effects on ability to drive and use machines have been observed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Adverse reactions to albumin are rare. Such reactions may be allergic in nature or due to high plasma protein levels from excessive albumin administration. Allergic manifestations include urticaria, chills, fever, and changes in respiration, pulse and blood pressure. Mild reactions such as flushing, urticaria, fever and nausea occur rarely. These reactions normally disappear rapidly when the infusion rate is slowed down or the infusion is stopped.</p><p>Very rarely, severe reactions such as shock may occur. In these cases, the infusion should be stopped and appropriate treatment should be initiated.</p><p>Post-marketing experience:</p><p>Additional side effects reported spontaneously include rigors, hypertension, hypotension, feeling cold, tachycardia, tremor, bronchospasm, dyspnoea, chest tightness, stridor and dizziness.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Hypervolemia may occur if the dosage and rate of infusion are too high. At the first clinical signs of cardiovascular overload (headache, dyspnea, jugular vein congestion), or increased blood pressure, raised central venous pressure and pulmonary edema, the infusion should be&nbsp;stopped immediately and the patient&rsquo;s hemodynamic parameters carefully monitored.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: plasma substitutes and plasma protein fractions, ATC code: B05AA01.</p><p>Each 50 mL vial of Plasbumin-20 supplies the oncotic equivalent of approximately 200 mL citrated plasma.</p><p>When administered intravenously to an adequately hydrated subject, the oncotic (colloid osmotic) effect of 50 mL Plasbumin-20 is such that it will draw approximately a further 125 mL of fluid from the extravascular tissues into the circulation within 15 minutes, thus increasing the total blood volume and reducing both hemoconcentration and whole blood viscosity. Accordingly, the main clinical indications are for hypoproteinemic states involving reduced oncotic pressure, with or without accompanying edema. Plasbumin-20 can also be used as a plasma volume expander.</p><p>Albumin is a transport protein and it may be useful in severe hemolytic disease in the neonate who is awaiting exchange transfusion. The infused albumin may reduce the level of free bilirubin in the blood. This could also be of importance in acute liver failure where albumin might serve the dual role of supporting plasma oncotic pressure, as well as binding excessive plasma bilirubin.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Under normal conditions, the total exchangeable albumin pool is 4-5 g/kg body weight, of which 40-45% is present intravascularly and 55-60% in the extravascular space. Increased capillary permeability will alter albumin kinetics and abnormal distribution may occur in condition such as severe burns or septic shock.</p><p>Under normal conditions, the average half-life of albumin is about 19 days. The balance between synthesis and breakdown is normally achieved by feedback regulation. Elimination is predominantly intracellular and due to the lysosome proteases.</p><p>In healthy subjects, less than 10% of the infused albumin leaves the intravascular compartment during the first 2 hours following infusion. There is considerable individual variation in the effect on plasma volume. In some patients the plasma volume can remain increased for some hours. However, in critically ill patients, albumin can leak out of the vascular space in substantial amounts at an unpredictable rate.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Human albumin is a normal constituent of human plasma and acts like physiological albumin.</p><p>In animals, single dose toxicity testing is of little relevance and does not permit the evaluation of toxic or lethal doses or of a dose-effect relationship. Repeated dose toxicity testing is impracticable due to the development of antibodies to heterologous protein in animal models.</p><p>To date, human albumin has not been reported to be associated with embryo-fetal toxicity, oncogenic or mutagenic potential.</p><p>No signs of acute toxicity have been described in animal models.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><img src="data:image/png;base64,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" alt="" width="1018" height="527" vspace="0" hspace="0" border="0" style="width:1018px;height:527px;margin-top:0px;margin-bottom:0px;margin-left:0px;margin-right:0px;border:0px solid black;" /></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>As with any hyperoncotic protein solution likely to be administered in large volumes, severe hemolysis and acute renal failure may result from the inappropriate use of Sterile Water for Injection as a diluent for Albumin (Human) 20%. Acceptable diluents include 0.9% Sodium Chloride or 5% Dextrose in Water. Please refer to the Posology and Method of Administration section for recommended diluents.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                36 months when stored at not more than 30ºC (86ºF)
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store at room temperature not exceeding 30&deg;C (86&deg;F). Do not freeze. Do not use after expiration date.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Plasbumin-20 is available in 50 mL and 100 mL rubber-stoppered vials. Each single dose vial contains albumin in the following approximate amounts:</p><p>- Size 50 mL, Grams Albumin 10.0<br />- Size 100 mL, Grams Albumin 20.0</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Preparation for Administration</p><p>Remove seal to expose stopper. Always swab stopper top immediately with a suitable antiseptic prior to entering vial.</p><p>Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.</p><p>Only 16 gauge needles or dispensing pins should be used with 20 mL vial sizes and larger. Needles or dispensing pins should only be inserted within the stopper area delineated by the raised ring. The stopper should be penetrated perpendicular to the plane of the stopper within the ring.</p><p>Administration</p><p>Plasbumin-20 should always be administered by intravenous infusion.</p><p>Solutions which have been frozen should not be used. Do not use if turbid. Do not begin administration more than 4 hours after the container has been entered. Partially used vials must be discarded. Vials which are cracked or which have been previously entered or damaged should not be used, as this may have allowed the entry of microorganisms.</p><p>Albumin (Human) 20%, USP (Plasbumin&reg;-20) contains no preservative.</p><p>Reconstitution</p><p>Not Applicable</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Grifols Therapeutics Inc., Research Triangle Park, NC 27709, USA
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                September 2017
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>